Alpha Tau’s new cancer radiology method proves effective
The new method is designed to provide more powerful and focused treatment.
28 cancer centers were treated, and no severe or permanent side effects were reported. Prof. Aron Popovtzer from the Rabin Medical Center (Beilinson Hospital), who managed the Israeli part of the trial, said that the results were impressive, given the fact that the patients were adults who had undergone previous treatment. Alpha Tau said that it would continue testing the treatment on other types of cancer.
Alpha Tau was restarted in 2016 after a suspension of its activity, due to conflicts between the shareholders. The company is managed by CEO Uzi Sofer, former Brainsway CEO. The company’s technology was developed by Tel Aviv University researchers Prof. Itzhak Kelson and Prof. Yona Keisari.
A year ago, Alpha Tau raised $29 million in a financing round led by Shavit Capital, indicating the company’s intention of holding an IPO in the coming years, with a preference for a US stock exchange. Among the other participants in the round were the OurCrowd crowdfunding firm; Madison Ventures, the venture capital arm of Madison Pharma, an Israeli drug marketing company; and private investors Sir Ronald Cohen and Alan Patricof, founders of Apax Partners. Alpha Tau has raised a total of $72 million since it was founded, including $50 million since it was restarted under the name Alpha Tau.
Published by Globes, Israel business news – en.globes.co.il – on December 2, 2019
© Copyright of Globes Publisher Itonut (1983) Ltd. 2019